InsiderTrades.com logo
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits   |   Ad
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
>> Register for the Workshop Now
William John Sibold net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

William Sibold Biography and Net Worth

CEO of Madrigal Pharmaceuticals
Mr. Sibold has more than 30 years of experience in the biopharmaceutical industry. Prior to joining Madrigal, he served as Executive Vice President, Specialty Care of Sanofi and President, Sanofi North America, where he led a global organization of approximately 10,000 employees across five specialty therapeutic areas and served as a member of the Sanofi Executive Committee. Previously, Mr. Sibold served as Chief Commercial Officer of Avanir Pharmaceuticals, President and CEO of Lycera Corp., and Senior Vice President U.S. Commercial for Biogen.

What is William John Sibold's net worth?

The estimated net worth of William John Sibold is at least $17.24 million as of September 9th, 2024. Mr. Sibold owns 55,887 shares of Madrigal Pharmaceuticals stock worth more than $17,237,786 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Sibold may own. Learn More about William John Sibold's net worth.

How old is William John Sibold?

Mr. Sibold is currently 58 years old. There are 5 older executives and no younger executives at Madrigal Pharmaceuticals. The oldest executive at Madrigal Pharmaceuticals is Dr. Rebecca A. Taub M.D., Founder, Chief Medical Officer, President of Research & Development and Director, who is 72 years old. Learn More on William John Sibold's age.

How do I contact William John Sibold?

The corporate mailing address for Mr. Sibold and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on William John Sibold's contact information.

Has William John Sibold been buying or selling shares of Madrigal Pharmaceuticals?

William John Sibold has not been actively trading shares of Madrigal Pharmaceuticals within the last three months. Most recently, William John Sibold sold 6,363 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $243.83, for a transaction totalling $1,551,490.29. Following the completion of the sale, the chief executive officer now directly owns 55,887 shares of the company's stock, valued at $13,626,927.21. Learn More on William John Sibold's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 192,284 shares worth more than $42,873,872.98. The most recent insider tranaction occured on December, 3rd when Director Fred B Craves sold 3,600 shares worth more than $1,135,116.00. Insiders at Madrigal Pharmaceuticals own 22.8% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 12/3/2024.

William John Sibold Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/9/2024Sell6,363$243.83$1,551,490.2955,887View SEC Filing Icon  
See Full Table

William John Sibold Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows William John Sibold's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $308.44
Low: $293.00
High: $312.52

50 Day Range

MA: $291.20
Low: $202.48
High: $354.85

2 Week Range

Now: $308.44
Low: $168.25
High: $368.29

Volume

716,661 shs

Average Volume

436,534 shs

Market Capitalization

$6.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits   |   Ad
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
>> Register for the Workshop Now